Soligenix, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Soligenix, Inc. – Product Pipeline Review – 2016’, provides an overview of the Soligenix, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Soligenix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Soligenix, Inc.

The report provides overview of Soligenix, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Soligenix, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Soligenix, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Soligenix, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Soligenix, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Soligenix, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Soligenix, Inc. Snapshot 5

Soligenix, Inc. Overview 5

Key Information 5

Key Facts 5

Soligenix, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Soligenix, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Combination Treatment Modalities 11

Soligenix, Inc. - Pipeline Products Glance 12

Soligenix, Inc. - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Soligenix, Inc. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Soligenix, Inc. - Early Stage Pipeline Products 15

IND/CTA Filed Products/Combination Treatment Modalities 15

Preclinical Products/Combination Treatment Modalities 16

Soligenix, Inc. - Drug Profiles 17

SGX-301 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

dusquetide 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

SGX-203 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

SGX-201 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

RiVax 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

SGX-202 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Ebola vaccine 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

human papillomavirus vaccine 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

RiVax + SGX-204 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

SGX-943 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Soligenix, Inc. - Pipeline Analysis 30

Soligenix, Inc. - Pipeline Products by Target 30

Soligenix, Inc. - Pipeline Products by Route of Administration 31

Soligenix, Inc. - Pipeline Products by Molecule Type 32

Soligenix, Inc. - Pipeline Products by Mechanism of Action 33

Soligenix, Inc. - Recent Pipeline Updates 34

Soligenix, Inc. - Dormant Projects 44

Soligenix, Inc. - Discontinued Pipeline Products 45

Discontinued Pipeline Product Profiles 45

BT-VACC 45

Soligenix, Inc. - Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Soligenix, Inc., Key Information 5

Soligenix, Inc., Key Facts 5

Soligenix, Inc. – Pipeline by Indication, 2016 7

Soligenix, Inc. – Pipeline by Stage of Development, 2016 9

Soligenix, Inc. – Monotherapy Products in Pipeline, 2016 10

Soligenix, Inc. – Combination Treatment Modalities in Pipeline, 2016 11

Soligenix, Inc. – Phase III, 2016 12

Soligenix, Inc. – Phase II, 2016 13

Soligenix, Inc. – Phase I, 2016 14

Soligenix, Inc. – IND/CTA Filed, 2016 15

Soligenix, Inc. – Preclinical, 2016 16

Soligenix, Inc. – Pipeline by Target, 2016 30

Soligenix, Inc. – Pipeline by Route of Administration, 2016 31

Soligenix, Inc. – Pipeline by Molecule Type, 2016 32

Soligenix, Inc. – Pipeline Products by Mechanism of Action, 2016 33

Soligenix, Inc. – Recent Pipeline Updates, 2016 34

Soligenix, Inc. – Dormant Developmental Projects,2016 44

Soligenix, Inc. – Discontinued Pipeline Products, 2016 45

Soligenix, Inc., Subsidiaries 46

List of Figures

List of Figures

Soligenix, Inc. – Pipeline by Top 10 Indication, 2016 7

Soligenix, Inc. – Pipeline by Stage of Development, 2016 9

Soligenix, Inc. – Monotherapy Products in Pipeline, 2016 10

Soligenix, Inc. – Pipeline by Target, 2016 30

Soligenix, Inc. – Pipeline by Route of Administration, 2016 31

Soligenix, Inc. – Pipeline by Molecule Type, 2016 32

Soligenix, Inc. – Pipeline Products by Mechanism of Action, 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports